Pharmaceutical major Lupin Ltd. has entered into a strategic license and supply agreement with Costa Rica-based SteinCares to commercialize its biosimilar ranibizumab in Latin America, excluding Mexico and Argentina. Under this collaboration, SteinCares will lead regulatory filings and distribution, while Lupin will retain responsibility for manufacturing. The move aligns with Lupin’s broader vision of increasing access to advanced biologic therapies in emerging markets. Ranibizumab, a biosimilar of a widely used monoclonal antibody targeting VEGF-A, is approved for multiple retinal diseases. The partnership underscores the growing momentum in biosimilars and highlights the companies’ commitment to accessible, high-quality eye care solutions.
Expanding Access to Retinal Therapies in Latin America
In a significant step aimed at advancing ophthalmologic care, Mumbai-headquartered Lupin Ltd. announced a licensing and supply agreement with SteinCares to market its biosimilar ranibizumab across Latin America—excluding the territories of Mexico and Argentina. This agreement marks Lupin’s continued push into emerging markets through targeted biosimilar collaborations.
Under the terms of the deal, SteinCares will take charge of all regulatory submissions, market registrations, and commercialization strategies for ranibizumab across the designated Latin American countries. Lupin will oversee manufacturing from its biologics facilities, ensuring quality and supply continuity.
Understanding Ranibizumab and Its Therapeutic Significance
Ranibizumab is a recombinant, humanized IgG1 monoclonal antibody fragment designed to inhibit vascular endothelial growth factor A (VEGF-A)—a protein that plays a critical role in abnormal blood vessel formation. It is widely used in treating several severe ophthalmic conditions.
The therapeutic indications for ranibizumab include:
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)
- Myopic Choroidal Neovascularization (mCNV)
These diseases are among the leading causes of vision impairment globally. With the biosimilar version, Lupin aims to provide an affordable and high-quality treatment option to patients who may otherwise lack access to such therapies due to cost barriers.
Strategic Vision and Executive Commentary
Cyrus Karkaria, President of Biotechnology at Lupin, emphasized the company’s mission to enhance retinal care accessibility. “Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients,” Karkaria stated. The move is part of Lupin’s broader initiative to make specialized biologics widely available in markets where cost-effective alternatives are in high demand.
The collaboration also underscores Lupin’s capability in biologics manufacturing, an increasingly important segment in the global pharmaceutical industry as patents on originator biologics continue to expire.
Market Impact and Outlook
Following the announcement, shares of Lupin traded marginally lower, down 0.32% to Rs. 1,972.80 apiece on the Bombay Stock Exchange. While the stock movement was modest, the agreement is likely to bolster the company’s long-term growth in biosimilars—an area with substantial untapped potential.
Latin America, with its expanding middle-class population and improving healthcare infrastructure, presents a strategic market for biosimilar adoption. The region's ophthalmology segment, in particular, is poised for rapid expansion given the increasing prevalence of diabetes and age-related vision disorders.
Conclusion: A Vision for Inclusive Innovation
Lupin’s agreement with SteinCares signals a deliberate and forward-looking strategy to bridge gaps in specialty care across developing markets. By leveraging its biologics expertise and aligning with strong regional partners, Lupin is well-positioned to drive the next phase of biosimilar-led growth.
As the global pharmaceutical landscape continues to shift toward affordability and accessibility, partnerships like this highlight the role of Indian pharma in democratizing healthcare. Through this deal, Lupin takes a firm step toward redefining what’s possible in retinal care across Latin America.
Comments